Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the wedge cap could send price back to the green trendline for a higher-low around ~685 before another attempt up.
News supporting the bullish path:
1- Mounjaro (tirzepatide) UK price hike: Lilly will lift UK list prices by up to ~170% from Sept 1, 2025 (e.g., highest doses from ~£122 to ~£330), with pharmacies flagging stockpiling/shortages. This supports revenue/ASP but may draw scrutiny.
2- Phase 3 ATTAIN-2 (orforglipron, oral GLP-1): trial met primary & key secondary endpoints in patients with obesity/overweight and Type-2 diabetes; company guiding to global regulatory submissions this year. Reports cite ~10.5% mean weight loss at the top dose. Sentiment tailwind for the obesity franchise.
Invalidation: weekly close below ~622.
Not financial advice :)
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the wedge cap could send price back to the green trendline for a higher-low around ~685 before another attempt up.
News supporting the bullish path:
1- Mounjaro (tirzepatide) UK price hike: Lilly will lift UK list prices by up to ~170% from Sept 1, 2025 (e.g., highest doses from ~£122 to ~£330), with pharmacies flagging stockpiling/shortages. This supports revenue/ASP but may draw scrutiny.
2- Phase 3 ATTAIN-2 (orforglipron, oral GLP-1): trial met primary & key secondary endpoints in patients with obesity/overweight and Type-2 diabetes; company guiding to global regulatory submissions this year. Reports cite ~10.5% mean weight loss at the top dose. Sentiment tailwind for the obesity franchise.
Invalidation: weekly close below ~622.
Not financial advice :)
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.